

2010 BIOTECHNOLOGY RESEARCH REVIEW.....	I
FOREWORD	I
CHAPTER ONE: CHIRAL TECHNOLOGY: GLOBAL MARKETS (BIO012E).....	1
INTRODUCTION	1
STUDY OBJECTIVES	1
REASONS FOR DOING THIS STUDY	1
INTENDED AUDIENCE.....	2
SCOPE OF THE STUDY	2
METHODOLOGY.....	2
INFORMATION SOURCES	2
ABOUT THE AUTHOR	3
RELATED BCC RESEARCH REPORTS.....	3
BCC ONLINE SERVICES	3
DISCLAIMER.....	4
SUMMARY.....	4
SUMMARY (CONTINUED)	5
<i>TABLE 1 WORLDWIDE REVENUE OF CHIRAL TECHNOLOGY</i>	
<i>MARKET, THROUGH 2014 (\$ MILLIONS)</i>	6
<i>FIGURE 1 WORLDWIDE REVENUE OF CHIRAL TECHNOLOGY</i>	
<i>MARKET, 2007-2014 (\$ MILLIONS)</i>	6
OVERVIEW.....	7
DEFINITIONS	7
Chirality.....	7
Racemic Mixture.....	7
Enantiomers.....	7
Diastereoisomers	7
Stereoisomer	7
Achiral.....	7
ISOMERS AND ISOMERISM.....	8
GENERAL CHARACTERISTICS OF ISOMERS	8
TYPES OF ISOMERS	8
Structural Isomerism	8
Skeletal Isomers.....	9
Positional Isomers.....	9
Functional Isomers	9
Stereoisomerism	9
Geometric Isomerism.....	9
<i>FIGURE 2 EXAMPLE 1 FOR GEOMETRIC ISOMERISM</i>	10
<i>FIGURE 3 EXAMPLE 2 FOR GEOMETRIC ISOMERISM</i>	10
<i>FIGURE 4 EXAMPLE 3 FOR GEOMETRIC ISOMERISM</i>	11
Properties of Geometric Isomers.....	11
Optical Isomerism.....	11
Properties of Optical Isomers	12
CHIRAL TECHNOLOGY	13

CHIRAL SYNTHESIS	13
METHODS OF CHIRAL SYNTHESIS	13
Chiral Pool Synthesis	13
Asymmetric Induction	14
Chiral Auxiliaries	14
Asymmetric Catalysis.....	15
Metal Ligand Complexes Derived from Chiral Ligands.....	15
Chiral Organocatalysts.....	15
Biocatalysts	16
Types of Asymmetric Catalytic Oxidation Reactions	16
PRODUCTS FOR CHIRAL SYNTHESIS	17
Chiral Intermediates	17
Different Types of Chiral Intermediates.....	18
Chiral Amino Acids.....	18
Chiral Epoxides and Glycidols.....	19
Saturated Chiral Propionic Acids.....	19
<i>TABLE 2 CHIRAL INTERMEDIATES FOR VARIOUS ENZYME INHIBITORS</i>	<i>19</i>
<i>TABLE 2 (CONTINUED).....</i>	<i>20</i>
Chiral Catalyst	20
Chiral Acid Catalysts	21
Biocatalysts or Enzymes	22
Chiral Auxiliaries	22
Chiral Reagents	23
CHIRAL SEPARATION OR RESOLUTION	23
RESOLUTION BY CRYSTALLIZATION	24
CHIRAL-RESOLVING AGENTS	24
CHIRAL COLUMN CHROMATOGRAPHY	25
KINETIC RESOLUTION.....	25
<i>TABLE 3 PRODUCTION OF COMPOUNDS BY ENZYMATIC RESOLUTION</i>	<i>26</i>
 CHAPTER TWO: DNA SEQUENCING: EMERGING TECHNOLOGIES AND APPLICATIONS (BIO045C).....	 27
INTRODUCTION	27
STUDY GOALS AND OBJECTIVES	27
REASONS FOR DOING THE STUDY.....	27
INTENDED AUDIENCE.....	28
SCOPE OF REPORT.....	29
METHODOLOGY.....	29
INFORMATION SOURCES	29
RELATED BCC REPORTS.....	29
ANALYST CREDENTIALS	30
SUMMARY.....	30

<i>TABLE 4 GLOBAL VALUE OF DNA SEQUENCING PRODUCTS, BY END-USE APPLICATION, THROUGH 2015 (\$ MILLIONS)</i>	31
<i>FIGURE 5 GLOBAL VALUE OF DNA SEQUENCING PRODUCTS, BY END-USE APPLICATION, 2009-2015 (\$ MILLIONS)</i>	32
SUMMARY (CONTINUED)	33
OVERVIEW.....	33
INTRODUCTION.....	33
Introduction (Continued).....	34
<i>TABLE 5 SCOPE OF THIS REPORT</i>	35
MARKET POTENTIAL OF DNA SEQUENCING PRODUCTS.....	35
<i>TABLE 6 GLOBAL VALUE OF DNA SEQUENCING WORKFLOW PRODUCTS, BY TYPE, THROUGH 2015 (\$ MILLIONS)</i>	36
SEQUENCING INDUSTRY GROWTH DRIVING FORCES.....	36
<i>TABLE 7 DNA SEQUENCING KEY GROWTH DRIVING FORCES</i>	37
Sequencing Industry Growth ... (Continued).....	37
SEQUENCING PRODUCTS	38
Sequencing Instruments	38
Sequencing Consumables	39
SEQUENCING PRODUCT LIFE CYCLE STATUS	39
<i>TABLE 8 PRODUCT LIFE CYCLE STATUS OF SEQUENCING PLATFORMS</i>	40
COMMERCIAL STATUS.....	41
SEQUENCING INDUSTRY	41
<i>TABLE 9 SEQUENCING INSTRUMENT COMPETITORS, BY TECHNOLOGY</i>	42
DNA SEQUENCING TECHNOLOGIES	43
GENETIC ANALYSIS	43
<i>FIGURE 6 CENTRAL MOLECULAR BIOLOGY DOGMA</i>	43
<i>FIGURE 7 DNA, MRNA, AND GENETIC VARIATION</i>	44
Genetic Analysis (Continued)	45
<i>TABLE 10 SCOPE OF KEY GENETIC ANALYSIS TECHNOLOGIES</i>	46
HISTORY OF DNA SEQUENCING.....	47
<i>TABLE 11 DNA SEQUENCING HISTORICAL TIMELINE</i>	47
<i>TABLE 11 (CONTINUED)</i>	48
History of DNA Sequencing (Continued).....	49
History of DNA Sequencing (Continued).....	50
History of DNA Sequencing (Continued).....	51
History of DNA Sequencing (Continued).....	52
<i>FIGURE 8 SEQUENCING COST TREND, BASE PAIRS SEQUENCED PER DOLLAR</i>	53
<i>FIGURE 9 SEQUENCING THROUGHPUT TREND</i>	54
<i>FIGURE 10 HUMAN GENOME SEQUENCING COST TREND, 2000- 2015 (DOLLARS)</i>	55
<i>FIGURE 11 \$1,000 GENOME PRODUCT SPACE</i>	56

OVERVIEW OF SEQUENCING TECHNOLOGIES.....	56
<i>TABLE 12 DNA SEQUENCING TECHNOLOGY PLATFORM COMPARISON.....</i>	<i>57</i>
Overview of Sequencing Technologies (Continued)	58
CHAPTER THREE: BIOLOGICAL THERAPIES FOR CANCER:	
THERAPIES AND GLOBAL MARKETS (BIO048B)	59
INTRODUCTION	59
STUDY GOALS AND OBJECTIVES	59
REASONS FOR DOING THE STUDY.....	59
SCOPE OF REPORT.....	60
INTENDED AUDIENCE.....	60
METHODOLOGY.....	61
RELATED BCC STUDIES	61
ANALYST CREDENTIALS	61
SUMMARY.....	61
SUMMARY (CONTINUED)	62
<i>TABLE 13 GLOBAL BIOLOGICAL TREATMENT OF CANCER: MARKET BY REGION, THROUGH 2014 (\$ MILLIONS).....</i>	<i>63</i>
<i>FIGURE 12 GLOBAL BIOLOGICAL TREATMENT OF CANCER: MARKET BY REGION, 2008–2014 (\$ MILLIONS).....</i>	<i>64</i>
OVERVIEW.....	64
GLOBAL CANCER MARKET	65
<i>TABLE 14 ESTIMATED GLOBAL INCIDENCE OF CANCER AND FORECAST BY REGION, 2007–2030 (MILLIONS).....</i>	<i>66</i>
<i>FIGURE 13 ESTIMATED GLOBAL CANCER INCIDENCE AND FORECAST BY REGION, 2008–2030 (\$ MILLIONS)</i>	<i>66</i>
<i>TABLE 15 ESTIMATED GLOBAL CANCER-RELATED DEATHS AND FORECAST BY REGION, 2007–2030 (MILLIONS).....</i>	<i>67</i>
<i>FIGURE 14 ESTIMATED GLOBAL CANCER-RELATED DEATHS AND FORECAST BY REGION, 2008 AND 2030 (MILLIONS)</i>	<i>68</i>
GLOBAL ONCOLOGY MARKET	69
<i>TABLE 16 GLOBAL ONCOLOGY MARKET SALES AND FORECAST BY REGION, THROUGH 2014 (\$ MILLIONS).....</i>	<i>69</i>
<i>FIGURE 15 GLOBAL ONCOLOGY MARKET SALES AND FORECAST BY REGION, 2008–2014 (\$ MILLIONS).....</i>	<i>70</i>
Global Oncology Market (Continued)	71
<i>TABLE 17 GLOBAL ONCOLOGY COMPANY SALES, THROUGH 2014 (\$ MILLIONS).....</i>	<i>72</i>
EMERGING MARKETS	73
<i>TABLE 18 ONCOLOGY MARKET IN ASIA-PACIFIC BY COUNTRY, 2006–2008 (\$ MILLIONS)</i>	<i>73</i>
<i>FIGURE 16 ONCOLOGY MARKET IN ASIA-PACIFIC BY COUNTRY, 2006–2008 (\$ MILLIONS)</i>	<i>74</i>
GLOBAL CANCER BIOLOGICAL THERAPEUTIC MARKET	75

<i>TABLE 19 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, 2008–2014 (\$ MILLIONS)</i>	75
<i>FIGURE 17 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, 2008–2014 (\$ MILLIONS)</i>	76
<i>TABLE 20 GLOBAL BIOLOGICAL TREATMENT OF CANCER: MARKET FORECAST BY DRUG CLASS, THROUGH 2014 (\$ MILLIONS)</i>	76
<i>FIGURE 18 GLOBAL BIOLOGICAL TREATMENT OF CANCER: MARKET BY DRUG CLASS FORECAST, 2008–2014 (\$ MILLIONS)</i>	77
Size and Growth of the Cancer Biotherapeutics Market	77
<i>TABLE 21 GLOBAL BIOLOGICAL TREATMENT OF CANCER: MARKET FORECAST BY PRODUCT, THROUGH 2014 (\$ MILLIONS)</i>	78
Issues and Trends Affecting the Market	79
Issues and Trends ... (Continued).....	80
Issues and Trends ... (Continued).....	81
CHAPTER FOUR: GLOBAL BIOCHIP MARKETS: MICROARRAYS AND LAB-ON-A-CHIP (BIO049C)	82
INTRODUCTION	82
STUDY GOALS AND OBJECTIVES	82
REASONS FOR DOING THE STUDY	82
INTENDED AUDIENCE	83
SCOPE OF REPORT	83
INFORMATION SOURCES	84
ANALYST CREDENTIALS	84
RELATED BCC REPORTS	85
SUMMARY	85
<i>TABLE 22 GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, THROUGH 2014 (\$ MILLIONS)</i>	86
<i>FIGURE 19 GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, 2007-2014 (\$ MILLIONS)</i>	86
SUMMARY (CONTINUED)	87
OVERVIEW	87
INTRODUCTION	87
Introduction (Continued).....	88
<i>TABLE 23 BIOLOGY DOWNSIZING REVOLUTION</i>	89
<i>FIGURE 20 EVOLUTION OF BIOCHIPS</i>	90
BIOCHIP TYPES	91
<i>FIGURE 21 CLASSIFICATION OF BIOCHIPS</i>	92
<i>TABLE 24 COMPARISON OF THE TWO MAJOR BIOCHIP TYPES</i>	93
<i>TABLE 25 BIOCHIP NOMENCLATURE</i>	94
BIOCHIP TECHNOLOGIES COVERED IN THIS REPORT.....	95
<i>TABLE 26 SCOPE OF THIS REPORT, BIOCHIP TECHNOLOGIES</i>	95
WHAT IS NEW IN THIS REPORT	96

MARKET POTENTIAL OF BIOCHIPS	96
<i>TABLE 27 GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, THROUGH 2014 (\$ MILLIONS)</i>	97
<i>TABLE 28 GLOBAL VALUE OF BIOCHIP MARKET BY END USE, THROUGH 2014 (\$ MILLIONS)</i>	98
DRIVING FORCES FOR GROWTH IN BIOCHIPS MARKETS	98
<i>TABLE 29 PRIMARY FORCES DRIVING OVERALL BIOCHIPS GROWTH</i>	99
Driving Forces for Growth in Biochips... (Continued)	100
BIOCHIPS: A CONVERGENCE OF DIVERSE TECHNOLOGIES	101
<i>TABLE 30 MULTIDISCIPLINARY FIELD OF BIOCHIPS</i>	101
LIFE CYCLE STATUS OF BIOCHIP PRODUCTS	102
<i>TABLE 31 LIFE CYCLE STATUS OF BIOCHIP TYPES</i>	102
COMMERCIAL STATUS OF BIOCHIPS	103
Microarrays	103
LOAC	104
THE BIOCHIP INDUSTRY	104
<i>TABLE 32 BIOCHIP INDUSTRY KEY COMPETITORS</i>	105
MICROARRAY TECHNOLOGIES	105
INTRODUCTION	105
The Nanoscale World.....	105
<i>TABLE 33 THE NANOSCALE WORLD</i>	106
<i>TABLE 34 MICROARRAY TYPES</i>	106
<i>TABLE 35 COMPARISON OF DNA AND PROTEIN MICROARRAY TECHNOLOGIES</i>	107
The Nanoscale World (Continued)	108
DNA MICROARRAY TECHNOLOGIES	109
Introduction	109
<i>FIGURE 22 MICROARRAY FEATURE DENSITY</i>	109
<i>FIGURE 23 MICROARRAY RESOLUTION</i>	109
<i>TABLE 36 MICROARRAY GENOME CONTENT</i>	110
<i>TABLE 37 DNA MICROARRAY PLATFORM FEATURES</i>	111
<i>TABLE 38 DNA MICROARRAY PLATFORM COMPARISON FOR MAJOR MANUFACTURERS</i>	112
Introduction (Continued)	113
Introduction (Continued)	114

CHAPTER FIVE: THERAPEUTIC VACCINES: THE GLOBAL MARKET

(BIO052B)	115
INTRODUCTION	115
STUDY GOALS AND OBJECTIVES	115
REASONS FOR DOING THIS STUDY	115
INTENDED AUDIENCE	115
SCOPE OF REPORT	116

METHODOLOGY.....	116
INFORMATION SOURCES	117
AUTHOR'S CREDENTIALS	117
RELATED BCC REPORTS.....	117
SUMMARY.....	117
SUMMARY (CONTINUED)	118
<i>TABLE 39 THE WORLDWIDE MARKET FOR THERAPEUTIC VACCINES BY INDICATION, THROUGH 2014 (\$ MILLIONS)</i>	119
<i>FIGURE 24 THE WORLDWIDE MARKET FOR THERAPEUTIC VACCINES BY INDICATION, 2010-2014</i>	119
OVERVIEW.....	120
DEFINITION OF A THERAPEUTIC VACCINE	120
IMMUNE SYSTEM OVERVIEW: CAST OF CHARACTERS.....	120
B-Cells, T-Cells and Antigen-Presenting Cells	120
B-Cells	120
T-Cells	121
Antigen-Presenting Cells.....	121
CELLULAR VERSUS HUMORAL IMMUNITY	121
INNOVATIVE APPROACHES TO VACCINE TECHNOLOGY.....	122
DNA Vaccines	122
Carbohydrate Vaccines.....	122
THE ROLE OF ADJUVANTS	123
ATTRACTIVE FEATURES OF THERAPEUTIC VACCINES VERSUS OTHER CLASSES OF THERAPIES	124
<i>TABLE 40 FEATURES OF THERAPEUTIC VACCINES VERSUS OTHER DRUG CLASSES</i>	124
THERAPEUTIC VACCINES APPROVED FOR CLINICAL USE OR IN CLINICAL TRIALS.....	124
<i>TABLE 41 THERAPEUTIC VACCINES IN CLINICAL TRIALS, ORDERED BY PHASE</i>	124
<i>TABLE 41 (CONTINUED)</i>	125
<i>TABLE 41 (CONTINUED)</i>	126
<i>TABLE 41 (CONTINUED)</i>	127
<i>TABLE 41 (CONTINUED)</i>	128
<i>TABLE 42 NUMBER OF THERAPEUTIC VACCINES IN CLINICAL TRIALS, BY PHASE</i>	128
<i>FIGURE 25 VACCINES IN CLINICAL TRIALS BY INDICATION, 2010 (%)</i>	129
<i>TABLE 43 VACCINES IN CLINICAL TRIALS BY TECHNOLOGY</i>	129
<i>TABLE 44 COMPANIES WITH THERAPEUTIC VACCINES IN CLINICAL TRIALS</i>	130
TECHNOLOGY OVERVIEW	130
TYPES OF THERAPEUTIC VACCINES.....	130

<i>TABLE 45 COMPARISON OF AUTOLOGOUS VERSUS ALLOGENEIC VACCINES</i>	131
<i>TABLE 46 NUMBER OF ALLOGENEIC AND AUTOLOGOUS THERAPEUTIC VACCINES IN DEVELOPMENT BY PHASE</i>	132

CHAPTER SIX: NEW DEVELOPMENTS IN TREATING GENETIC

DISORDERS: THE GLOBAL MARKET (BIO056B)	133
--	-----

INTRODUCTION	133
--------------------	-----

STUDY GOALS AND OBJECTIVES	133
----------------------------------	-----

REASONS FOR DOING THE STUDY.....	133
----------------------------------	-----

SCOPE OF REPORT.....	133
----------------------	-----

METHODOLOGY.....	134
------------------	-----

ANALYST CREDENTIALS	135
---------------------------	-----

RELATED BCC STUDIES	135
---------------------------	-----

SUMMARY.....	135
--------------	-----

 GENETIC DISORDER MARKETS: MAJOR MARKETS

SUMMARY.....	135
--------------	-----

<i>TABLE 47 GLOBAL GENETIC DISORDER PRODUCT REVENUES BY MAJOR MARKET SEGMENT, THROUGH 2014 (\$ MILLIONS)</i>	136
--	-----

<i>FIGURE 26 GLOBAL GENETIC DISORDER PRODUCT REVENUES, 2007-2014 (\$ MILLIONS)</i>	137
--	-----

LEADING MANUFACTURERS.....	137
----------------------------	-----

<i>TABLE 48 TOTAL COMPANY SALES FOR GENETIC DISORDER TREATMENT, 2009 (\$ MILLIONS)</i>	138
--	-----

INDUSTRY OVERVIEW	138
-------------------------	-----

INTRODUCTION.....	138
-------------------	-----

HISTORY OF GENETIC RESEARCH.....	138
----------------------------------	-----

OVERVIEW OF DNA AND GENES	139
---------------------------------	-----

The Human Genome Project.....	140
-------------------------------	-----

HapMap Project.....	140
---------------------	-----

TERMINOLOGY	140
-------------------	-----

<i>TABLE 49 GLOSSARY OF GENETIC TERMS</i>	141
---	-----

<i>TABLE 49 (CONTINUED)</i>	142
-----------------------------------	-----

<i>TABLE 49 (CONTINUED)</i>	143
-----------------------------------	-----

<i>TABLE 49 (CONTINUED)</i>	144
-----------------------------------	-----

<i>TABLE 49 (CONTINUED)</i>	145
-----------------------------------	-----

<i>TABLE 49 (CONTINUED)</i>	146
-----------------------------------	-----

<i>TABLE 49 (CONTINUED)</i>	147
-----------------------------------	-----

GENES AND FAMILY HISTORY.....	148
-------------------------------	-----

OVERVIEW OF GENETIC DISORDERS.....	148
------------------------------------	-----

Gene Mutations	148
----------------------	-----

Causes of Gene Mutations.....	149
-------------------------------	-----

GENETIC TESTING AND SCREENING.....	150
------------------------------------	-----

Testing Population Groups (Ethnogenetics).....	151
--	-----

Direct to Consumer Genetic Testing.....	151
---	-----

U.S. DEMOGRAPHICS	152
TABLE 50 NUMBER OF BIRTHS IN THE U.S., 2006-2010	152
TABLE 51 POPULATION GROWTH AND BIRTH STATISTICS U.S., 2011-2020 (THOUSANDS).....	153
FIGURE 27 POPULATION GROWTH AND BIRTH STATISTICS U.S. 2011-2020 (THOUSANDS).....	154
INTERNATIONAL DEMOGRAPHICS.....	155
TABLE 52 ESTIMATED WORLD POPULATION AND ANNUAL GROWTH BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS).....	155
FIGURE 28 ESTIMATED WORLD POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 (MILLIONS)	155
TABLE 53 WORLD POPULATION BY SELECTED COUNTRIES, THROUGH 2014 (MILLIONS).....	156
FIGURE 29 WORLD POPULATION BY SELECTED COUNTRIES, 2007- 2014 (MILLIONS).....	157
International Birth Rate Statistics.....	157
TABLE 54 BIRTHS FOR SELECTED COUNTRIES, 1995-2015 (THOUSANDS).....	158
FIGURE 30 BIRTHS FOR SELECTED COUNTRIES, 1995-2015 (THOUSANDS).....	158
ISSUES AFFECTING THE MARKET	159
GENETIC RESEARCH.....	159
GENE THERAPY COMPARED TO CELL THERAPY	159
ISSUES WITH HUMAN CLONING	160
LEGISLATIVE ISSUES	160
The Genetic Information Nondiscrimination Act (GINA).....	160
German Legislation	161
Australian Genetic Testing Law	161
European Union Action in the Field of Rare Diseases.....	162
GENETICS CLINICS.....	162
TABLE 55 NUMBER OF GENETIC CLINICS BY COUNTRY	163
GENOME SEQUENCING TECHNOLOGY	163
Technological Applications of Genome Sequencing	164
Sequencing Costs	164
CHAPTER SEVEN: EPIGENOMICS: EMERGING OPPORTUNITIES IN BIOMARKERS, DIAGNOSTICS AND THERAPEUTICS (BIO059B)	165
INTRODUCTION	165
STUDY GOALS AND OBJECTIVES	165
REASONS FOR DOING THE STUDY.....	165
INTENDED AUDIENCE.....	166
SCOPE OF REPORT.....	166
METHODOLOGY.....	166
INFORMATION SOURCES	167

RELATED BCC REPORTS.....	167
SUMMARY.....	167
<i>TABLE 56 GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY APPLICATION, THROUGH 2014 (\$ MILLIONS)</i>	168
<i>FIGURE 31 GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY APPLICATION, 2008-2014 (\$ MILLIONS)</i>	169
OVERVIEW.....	170
INTRODUCTION.....	170
THE NEW PARADIGM OF EPIGENOMICS.....	170
<i>FIGURE 32 EPIGENOMICS: A NEW PARADIGM</i>	171
HOW EPIGENOMICS FITS WITHIN GENOMICS.....	172
<i>TABLE 57 GENOMICS PLATFORMS</i>	172
How Epigenomics Fits Within ... (Continued).....	173
TECHNICAL SCOPE OF THIS REPORT.....	174
<i>TABLE 58 TECHNOLOGY SCOPE OF THIS REPORT</i>	174
MARKET POTENTIAL OF EPIGENOMICS.....	175
<i>TABLE 59 GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY APPLICATION, THROUGH 2014 (\$ MILLIONS)</i>	175
EPIGENOMICS PRODUCTS.....	176
Research Tools and Reagents.....	176
Diagnostics.....	177
Drugs.....	177
<i>FIGURE 33 ACTIVE CANCER EPIGENETIC DRUG CLINICAL TRIALS, BY PHASE AND INDICATION, JANUARY 2010</i>	178
GROWTH DRIVING FORCES.....	179
Growth in Life Science Funding.....	179
Creation of Epigenomic Maps.....	179
Aging Population in Developed Countries.....	179
NEED FOR BETTER CANCER THERAPIES.....	179
Growth in Personalized Medicine.....	180
WHY EPIGENETIC TECHNOLOGY IS IMPORTANT.....	180
<i>FIGURE 34 EPIGENETIC PROCESSES CAN GENERATE ABNORMAL CELLS DURING CELL DEVELOPMENT</i>	180
LIFE CYCLE STATUS OF EPIGENOMICS TECHNOLOGIES.....	181
HISTORICAL BACKGROUND.....	182
<i>TABLE 60 HISTORICAL OVERVIEW OF EPIGENOMICS</i>	182
Historical Background (Continued).....	183
THE EPIGENOMICS INDUSTRY.....	184
<i>TABLE 61 EPIGENOMICS INDUSTRY KEY COMPANIES</i>	185
EPIGENETIC TECHNOLOGIES.....	186
INTRODUCTION.....	186
EPIGENETIC ANALYSIS TECHNOLOGIES.....	186
<i>TABLE 62 EPIGENETIC ANALYSIS TECHNOLOGIES</i>	187
Status of DNA and Histone Analysis Technologies.....	187

<i>TABLE 63 STATUS OF DNA METHYLATION AND HISTONE ANALYSIS TECHNOLOGIES</i>	187
DNA and Histone Analysis Workflow.....	188
DNA and Histone Analysis ... (Continued)	189
<i>FIGURE 35 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS WORKFLOW</i>	190
DNA METHYLATION	190
Methylated Cytosine—A Fifth Base	190
<i>FIGURE 36 EPIGENETIC CHANGES TO DNA AFFECT GENE EXPRESSION</i>	191
Biological Role of DNA Methylation	191
<i>TABLE 64 BIOLOGICAL ROLES OF DNA METHYLATION</i>	192
DNA Methyltransferase Enzymes	193
CpG Islands	194
<i>TABLE 65 DESCRIPTION OF CPG ISLANDS</i>	195
HISTONE METHYLATION AND ACETYLATION.....	196
Histones	196
Histone Modifications.....	197
<i>FIGURE 37 ACETYLATION OF HISTONE TAIL REGIONS</i>	197
Histone Acetylation and Methylation Enzymes.....	198
<i>FIGURE 38 HISTONE ACETYLATION AND METHYLATION ENZYMES</i>	199
Histone Acetyl Transferases (HAT)	199
Histone Deacetylases (HDAC).....	199
<i>TABLE 66 HDAC ENZYMES CLASSES</i>	200
Histone Methyltransferases and Demethylases.....	200
Inappropriate Methylation and Acetylation.....	201
<i>TABLE 67 MECHANISMS FOR INAPPROPRIATE METHYLATION AND ACETYLATION</i>	201
 CHAPTER EIGHT: NUCLEIC ACID APTAMERS FOR DIAGNOSTICS AND THERAPEUTICS: GLOBAL MARKETS (BIO071A)	
INTRODUCTION	202
STUDY GOALS AND OBJECTIVES	202
REASONS FOR DOING THE STUDY.....	202
SCOPE OF REPORT.....	203
INTENDED AUDIENCE.....	203
INFORMATION SOURCES	203
ANALYST CREDENTIALS	203
RELATED BCC REPORTS.....	204
SUMMARY.....	204
<i>TABLE 68 GLOBAL MARKETS FOR APTAMERS, THROUGH 2014 (\$ MILLIONS)¹</i>	204
<i>FIGURE 39 GLOBAL MARKETS FOR APTAMERS, 2008-2014 (\$ MILLIONS)¹</i>	205

<i>TABLE 69 POTENTIAL MARKETS FOR APTAMER THERAPEUTICS, THROUGH 2014 (\$ MILLIONS)¹</i>	205
<i>TABLE 70 HISTORICAL U.S. SALES FOR MACUGEN, THE FIRST FDA-APPROVED APTAMER DRUG, 2005-2009 (\$ MILLIONS)</i>	206
<i>TABLE 71 POTENTIAL MARKETS FOR APTAMER-BASED IN-VITRO DIAGNOSTICS, THROUGH 2014 (\$ MILLIONS)¹</i>	206
OVERVIEW	207
INTRODUCTION: APTAMERS AS AFFINITY REAGENTS.....	207
<i>FIGURE 40 SIMPLIFIED SCHEMATIC OF SELEX PROCESS FOR IN-VITRO SELECTION OF (DNA) APTAMERS</i>	207
Aptamers as Superior Affinity Reagents.....	208
<i>TABLE 72 APTAMERS AND ANTIBODIES: KEY DIFFERENCES</i>	209
Industry Definition and Historical Development.....	209
Economic Importance	210
Product Life Cycle.....	211
Intellectual Property and regulatory Issues.....	211
Potential Future Developments	212
MARKETS BY TECHNOLOGY TYPE	213
INTRODUCTION.....	213
ENABLING TECHNOLOGY.....	214
Oligonucleotide Synthesis	214
Modified Oligonucleotides	215
Aptamer Modifications for Diagnostic Purposes	216
Nuclease Stability of Aptamers in the Body and ADME Properties	217
<i>TABLE 73 MODIFICATIONS EMPLOYED TO ENHANCE APTAMERS</i>	218
Nanoparticles and Quantum Dot Labels.....	218
Next-Generation Sequencing	219
<i>TABLE 74 CURRENT PRICE PER MEGABASE FOR 'NEXT GENERATION' DNA SEQUENCING (\$/MEGAPHASE)</i>	219
Surface Plasmon Resonance.....	220
Bioinformatics.....	220
Trends in Enabling Technologies.....	221
APTAMERS AS DIAGNOSTIC SENSORS.....	222
Self-reporting Sensors	222
Self-reporting Sensors (Continued).....	223
Sensor Platform Technologies.....	224
Homogeneous Solution Assays in Microplate Readers	224
Quartz Crystal Microbalance	225
Nano- and Microcantilever Sensors Using Aptamers.....	225
Nano- and ... (Continued)	226
Surface Plasmon Resonance (SPR) and SPR Arrays.....	227

Trends in Aptamers as Diagnostics	228
APTAMERS AS THERAPEUTICS.....	228
Aptamers as Therapeutics (Continued).....	229
Aptamers as Therapeutics (Continued).....	230
Aptamers and Infectious Disease	231
Aptamer Modifications	231
Aptamers as Imaging Labels	231
Application of Aptamers as Modifiers of Surgical Implants....	231
Whole Cell Selex	232
‘Captamers’	232
VEGF Aptamers	233
<i>TABLE 75 MEDICALLY RELEVANT APTAMER TARGETS</i>	<i>234</i>
MACUGEN’S PATH TO FDA APPROVAL.....	234
Macugen’s Path to FDA Approval (Continued)	235